incentivizing antibiotic research

Dr. David Shlaes has written numerous times on "pull incentives" to encourage new antibiotic discovery, and why professional societies (like the Infectious Diseases Society of America and the AMA) aren't providing enough input to emphasize the importance of emerging bacterial resistance. Today our ACSH advisor expands on both topics.
With the recent discovery of polymyxin-resistant infection here in the U.S., there's a renewed pledge among drug developers and the government to incentivize research for developing new antibiotics, previously a seemingly abandoned effort.